Skip to main content

Carrier Screening Market Growth Opportunities Investment Analysis Report 2021-2031

Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down’s syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA). Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health.

Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder. A person who is a carrier has only one gene for a disorder and usually does not have symptoms or have only mild symptoms. The current market for carrier screening is majorly dominated by manufacturers and service providers such as BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., and Yourgene Health Plc.

The global carrier screening market is projected to reach $4,479.0 million by 2031, growing from $1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.

The growth of the carrier screening market is expected to be driven by the decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications. However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers. 

 

Market Segmentation

• Panel Type (Expanded Carrier Screening and Targeted Carrier Screening)

• Product Type (In Vitro Diagnostics and Laboratory Developed Tests)

• Screening Type (Prenatal Carrier Screening and Preconception Carrier Screening)

• Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, and Other Technologies)

• Indication (Fragile X Syndrome, Cystic Fibrosis, Spinal Muscular Atrophy, Down’s Syndrome, Thalassemia, Tay-Sachs Disease, Huntington’s Disease, Sickle Cell Anemia, Hemophilia, and Other Indications)

Regional Segmentation


• North America: U.S., Canada

• Europe: Germany, France, U.K, Italy, Spain, Netherlands, Denmark, Belgium, Switzerland and Rest-of-Europe

• Asia-Pacific: China, Japan, India, South Korea, Australia, Singapore, Rest-of-Asia-Pacific

• Latin America: Brazil, Mexico, Rest-of-Latin America

• Rest-of-the-World

 

Competitive Landscape

The growth of this market can be majorly attributed to the presence of well-established guidelines regarding carrier screening, presence of established companies undertaking key business strategies, decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications, among others. Further, increasing focus on research pertaining to carrier screening such as targeted carrier screening in spinal muscle atrophy and emerging application of preconcecption carrier screening is also expected to support the growth of the carrier screening market during the forecast period, 2021-2031.

The growth of other technologies, such as next-generation sequencing and PCR can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders. Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Market Dynamics



 


Key Companies Profiled


BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., Yourgene Health Plc

Key Questions Answered in this Report:

• How is carrier screening revolutionizing the field of reproductive health?
• What are the major market drivers, challenges, and opportunities in the global carrier screening market?
• What are the underlying structures resulting in the emerging trends within the global carrier screening market?
• How is the COVID-19 pandemic impacting the global carrier screening ecosystem??
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of carrier screening?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Type (expanded carrier screening and targeted carrier screening)
o Product (in vitro diagnostics and laboratory developed tests)
o Carrier Screening Type (prenatal carrier screening and preconception carrier screening)
o Technology (next-generation sequencing, polymerase chain reaction, microarray, and other technologies)
o Indication (fragile X syndrome, cystic fibrosis, spinal muscular atrophy, Down’s Syndrome, thalassemia, Tay-Sachs Disease, Huntington’s Disease, sickle cell anemia, hemophilia, and other indications)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the carrier screening companies in the region of their operation?
• Who are the leading players with significant offerings in the global carrier screening market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Request Free Sample - https://bisresearch.com/requestsample?id=1237type=download

 

The report constitutes an in-depth study of the global carrier screening market. The study also presents a detailed analysis of the market dynamics and estimation of the market size over the forecast period, 2021-2031.

The scope of this report is focused on the analysis of the carrier screening market by type, product, carrier screening type, indication, technology, and region.

 

BIS Related Studies

Global Non-Invasive Prenatal Testing (NIPT) Market

 

Preimplantation Genetic Testing Market - A Global and Regional Analysis

Comments

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Digital PCR Market size,Share, Leading Players, Growth, Development and Demand Forecast to 2032

  Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring. The global  digital PCR market   is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022–2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development. Impact of COVID-19 The current global digital PCR market comprises kits and assays, system, and reagents and consuma...

Radiation Dose Management Market Likely To Increase Size, Shares, And Demand Forecast 2022-2032

  Radiation dose is the amount of radiation absorbed by a patient during a diagnostic imaging procedure. A large dose of radiation can cause tissue damage and increase the risk of developing cancer in later stages of life.The development of on-cloud dose management solutions and the growing initiatives on radiation dose management for pediatric procedures are some of the major opportunities in the global radiation dose management market. Furthermore, some of the key trends going on in the market include the increasing development of imaging modalities with technologies that lower radiation dose, partnerships and strategic business alliances dominating the market, and various collaborations among market players. The global  radiation dose management market   was valued at $212.8 million in 2021 and is anticipated to reach $586.7 million by 2032, witnessing a CAGR of 10.30% during the forecast period 2022–2032. The growth in the global radiation dose management market is ex...